1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 14,800 | 15,800 | 16:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Pharming Group N.V. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| Do | Pharming Group Sees Higher-than-Expected Revenues In Fiscal 2025 | 3 | RTTNews | ||
| Do | Pharming Group N.V.: Pharming Group reports preliminary 2025 revenues and announces Investor Day | 330 | GlobeNewswire (Europe) | Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full... ► Artikel lesen | |
| 08.12.25 | Pharming Group N.V.: Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit | 302 | GlobeNewswire (Europe) | Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit... ► Artikel lesen | |
| 06.11.25 | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 06.11.25 | Pharming GAAP EPS of $0.01 beats by $0.01, revenue of $97.3M beats by $4.46M | 6 | Seeking Alpha | ||
| 06.11.25 | Pharming Group N.V.: Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow | 484 | GlobeNewswire (Europe) | Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024... ► Artikel lesen | |
| 30.10.25 | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London | 427 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare... ► Artikel lesen | |
| 23.10.25 | Pharming Group N.V.: Pharming Group to report third quarter 2025 financial results and provide business update on November 6 | 381 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the... ► Artikel lesen | |
| 22.10.25 | Pharming Group N.V. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 20.10.25 | Pharming Group N.V.: Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio | 5 | GlobeNewswire (USA) | ||
| 06.10.25 | Pharming Group N.V.: Pharming Group provides update on previously announced G&A expense reduction plan | 309 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to... ► Artikel lesen | |
| 03.10.25 | FDA accepts supplemental New Drug Application for Pharming's paediatric immunodeficiency therapy | 4 | PMLiVE | ||
| 02.10.25 | Pharming Group-Aktie steigt nach FDA-Zulassung für Leniolisib bei Kindern | 4 | Investing.com Deutsch | ||
| 02.10.25 | Pharming Group stock rises as FDA approves leniolisib for pediatric APDS | 2 | Investing.com | ||
| 01.10.25 | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.10.25 | Pharming shares jump 6% as FDA grants priority review for Joenja in children | 4 | Investing.com | ||
| 01.10.25 | FDA Accepts Pharming's SNDA For Leniolisib In Pediatric APDS; Priority Review Granted | 4 | RTTNews | ||
| 01.10.25 | Pharming Group N.V.: Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years | 625 | GlobeNewswire (Europe) | If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision based... ► Artikel lesen | |
| 10.09.25 | Pharming Group N.V. - 6-K, Report of foreign issuer | 5 | SEC Filings |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 9,124 | +0,91 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,822 | +3,82 % | PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities | ||
| ATAIBECKLEY | 3,810 | -4,03 % | XETR NL0015000DX5: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTILATAI BECKLEY N.V.... ► Artikel lesen | |
| BIOMERIEUX | 114,40 | +0,18 % | BIOMERIEUX: bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health | ||
| BIO GREEN MED SOLUTION | 1,420 | +1,43 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 29,200 | -2,67 % | Dividendenbekanntmachungen (06.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AIRTEL AFRICA PLC GB00BKDRYJ47 0,0216 GBP 0,0245 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2949 EUR ASHMORE GROUP... ► Artikel lesen | |
| ANAPTYSBIO | 38,000 | +1,06 % | AnaptysBio, Inc.: Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology... ► Artikel lesen | |
| ABIONYX PHARMA | 3,705 | +0,95 % | ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA | Regulatory News:
Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on... ► Artikel lesen | |
| AKESO | 14,100 | -0,70 % | Akeso Secures NMPA Label Update For Ivonescimab With Dual Survival Benefits In NSCLC | ||
| XTL BIOPHARMACEUTICALS | 0,545 | +1,87 % | XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency | RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a notification letter from... ► Artikel lesen | |
| MEIRAGTX | 6,400 | +2,40 % | MeiraGTx inks $18.2M share purchase deal with Perceptive Advisors | ||
| MAAT PHARMA | 5,060 | -3,44 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
10.12.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,050 | -2,91 % | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| DIAGONAL BIO | 0,004 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| QIAGEN | 41,505 | +0,52 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,76 % bei einem Aktienkurs von 15,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.